BEAM vs CRSP
BEAM and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $2.87B | $5.07B |
| P/B | 3.01 | — |
| P/S | 20.5x | 1440.0x |
| Revenue | $146.64M(TTM) | — |
| Revenue growth (YoY) | 120.0% | -90.6% |
| Net income | -$108.35M(TTM) | — |
| Earnings growth (YoY) | 78.8% | -58.8% |
| EPS, diluted | $-0.88(TTM) | — |
| EBIT margin | -274.6% | -18933.6% |
| ROE | -8.4% | -35.3% |
| ROIC | -45.7% | -32.5% |
| 1y total return | +21.5% | — |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs CRSP
| Metric | BEAM | CRSP |
|---|---|---|
| End value | $14.8K | $9.6K |
| Total return | +47.8% | -3.7% |
| CAGR | +6.0% | -0.6% |
| Volatility | 79.5% | 61.5% |
| Sharpe | 0.41 | 0.23 |
| Sortino | 0.63 | 0.35 |
| Max drawdown | -89.1% | -85.1% |
Based on 1696 common trading days, 2020-02-06 → 2026-11-04 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)